On December 14, 2021 Aucentra reported that it is excited to be awarded a seed-start grant of $700k by the South Australian government’s research and innovation fund (Press release, Aucentra, DEC 14, 2021, View Source [SID1234606756]). This funding will be used to test Aucentra’s leading drug candidate Auceliciclib.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Auceliciclib, if successful in its clinical trials, will be a game-changing treatment of glioblastoma multiforme, which is the most aggressive type of brain cancer and the most difficult to treat.
The Minister for Innovation and Skills David Pisoni recognised Aucentra’s ground-breaking achievements; "I am incredibly proud of Professor Wang and her team at the University of South Australia for the amazing work they have accomplished".
Auceliciclib is a CDK4 and 6 inhibitor with a high specificity which allows for prevention of cancer cell growth and proliferation with fewer side effects. Read the full article here: View Source